Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cross-sensitivity between paroxetine and sertraline.

Caroline A Warnock1, Abbas G Azadian

  • 1Department of Pharmaceutical Services, Centre for Addiction and Mental Health, Toronto, Ontario, Canada. caroline_warnock@camh.net

The Annals of Pharmacotherapy
|March 29, 2002
PubMed
Summary

A case report suggests potential cross-sensitivity between selective serotonin-reuptake inhibitors (SSRIs). Patients experiencing dermatologic reactions to one SSRI may react to another, even with different chemical structures.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Psychotropic drug prescribing survey in a Canadian rehabilitation and complex care facility.

The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists·2014
Same author

Clozapine toxicity and hepatitis.

Journal of clinical psychopharmacology·2013
See all related articles

Area of Science:

  • Pharmacology
  • Dermatology
  • Clinical Medicine

Background:

  • Selective serotonin-reuptake inhibitors (SSRIs) are widely prescribed antidepressants.
  • Drug-induced skin reactions are a known concern with various medications.
  • Cross-reactivity between structurally similar drugs is a documented phenomenon.

Observation:

  • A 20-year-old male developed a maculopapular rash after initiating paroxetine.
  • Upon discontinuation of paroxetine and subsequent initiation of sertraline, a similar dermatologic reaction recurred.
  • The patient was of Southeast Asian descent.

Findings:

  • This case highlights a potential, unexpected cross-reactivity between SSRI antidepressants.
  • The observed reaction occurred despite differences in the chemical structures of paroxetine and sertraline.

Related Experiment Videos

  • Dermatologic adverse events may not be limited to a single SSRI agent.

    • Implications:

    • Clinicians should consider the possibility of SSRI cross-reactivity when patients develop skin reactions.
    • Alternative antidepressant classes may be warranted for patients with SSRI-induced dermatologic adverse events.
    • Further investigation into SSRI cross-reactivity is needed to guide clinical practice and patient safety.